What the bad jobs report means for markets
Michael J. Rider, Global General Counsel at ResMed Inc . (NYSE:RMD), a $34 billion medical equipment company with a perfect Piotroski Score of 9 according to InvestingPro, recently sold shares of the company, according to a Form 4 filing with the Securities and Exchange Commission. On March 3, Rider disposed of 64 shares of ResMed common stock at a price of $234.10 each, amounting to a total transaction value of $14,982. Following this transaction, Rider holds 8,910 shares in the company. The sale was conducted under a Rule 10b5-1 trading plan, which was adopted on May 11, 2024. ResMed maintains strong financial health with low debt levels and generally trades with low price volatility. InvestingPro analysis reveals 13 additional key insights about ResMed’s financial position and growth prospects in its comprehensive Pro Research Report.
In other recent news, ResMed Inc. reported its Q2 FY2025 earnings, surpassing analyst expectations with an earnings per share (EPS) of $2.43, compared to the forecast of $2.32. The company also exceeded revenue projections, posting $1.28 billion against the anticipated $1.27 billion. ResMed demonstrated a 10% increase in group revenue year-over-year, reflecting strong performance across its product lines and strategic focus on innovation and digital health solutions. The company maintained robust cash flow and declared a quarterly dividend of $0.53 per share. In addition, ResMed was recently added to Goldman Sachs’ APAC Director’s Cut Conviction List, indicating a positive outlook from the investment bank. This inclusion is based on expectations of strong patient growth and operating margin expansion, with projections of a compound annual growth rate of approximately 10% for group revenue from FY24 to FY27E. These recent developments underscore ResMed’s favorable position in the CPAP market and its growth potential in the coming years.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.